Journal
CANCERS
Volume 11, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/cancers11020191
Keywords
CAR T cells; solid tumors; novel approaches
Categories
Funding
- NCI NIH HHS [R01 CA136934, R01 CA193167] Funding Source: Medline
- NIH HHS [R01-CA193167, R01-CA136934] Funding Source: Medline
Ask authors/readers for more resources
Chimeric antigen receptor T cells (CAR T Cells) have led to dramatic improvements in the survival of cancer patients, most notably those with hematologic malignancies. Early phase clinical trials in patients with solid tumors have demonstrated them to be feasible, but unfortunately has yielded limited efficacy for various cancer types. In this article we will review the background on CAR T cells for the treatment of solid tumors, focusing on the unique obstacles that solid tumors present for the development of adoptive T cell therapy, and the novel approaches currently under development to overcome these hurdles.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available